2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Condition(s) studied
Investigational drug(s) / intervention(s)
Drug:Cisplatin: Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Study summary
The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.
Eligibility
Primary outcome measure(s)
- Failure-free survival (FFS) — 3 years
calculated from enrolment to the date of locoregional recurrence,distant metastasis,or death from any cause, whichever occurred first.
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou | Guangdong | Recruiting |
| Affiliated Hospital of Guilin Medical College | Guilin | Guangxi | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha | Hunan | Not Yet Recruiting |
| Xiangya Hospital, Central South University | Changsha | Hunan | Not Yet Recruiting |
| Jiangsu Cancer Hospital | Nanjing | Jiangsu | Not Yet Recruiting |
More Sun Yat-sen University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06492460 on ClinicalTrials.gov ↗ ← All trials in China